INNV vs NEO

INNV exhibits a stable financial foundation with a Piotroski F-Score of 6/9, but it is currently suffering from a severe valuation disconnect. The current price of $8.20 trades at a massive premium to both the Graham Number ($1.46) and the growth-based Intrinsic Value ($0.35). While the forward P/E of 24.12 suggests a significant earnings recovery is expected, the trailing P/E of 164.00 and thin profit margins (0.71%) indicate the stock is priced for perfection. Combined with bearish insider sentiment and a technical trend of 0/100, the risk-to-reward ratio is unfavorable.

NeoGenomics exhibits a stable financial foundation with a Piotroski F-Score of 5/9 and exceptional liquidity (Current Ratio 4.26), though it remains unprofitable with a -14.85% profit margin. While the company has a remarkable track record of beating earnings estimates and shows positive YoY EPS growth, this is offset by a disastrous 5-year price decline of 83.1% and bearish insider activity. The stock appears undervalued relative to analyst targets ($14.81), but the lack of current profitability and negative technical trends suggest a speculative recovery play rather than a value certainty.